nodes	percent_of_prediction	percent_of_DWPC	metapath
Vardenafil—CYP3A4—Thiotepa—sarcoma	0.0987	0.275	CbGbCtD
Vardenafil—CYP3A5—Vincristine—sarcoma	0.0749	0.209	CbGbCtD
Vardenafil—CYP3A5—Etoposide—sarcoma	0.0686	0.191	CbGbCtD
Vardenafil—CYP3A4—Mitoxantrone—sarcoma	0.0424	0.118	CbGbCtD
Vardenafil—CYP3A4—Vincristine—sarcoma	0.0292	0.0814	CbGbCtD
Vardenafil—CYP3A4—Etoposide—sarcoma	0.0268	0.0746	CbGbCtD
Vardenafil—PDE5A—pulmonary artery—sarcoma	0.0236	0.244	CbGeAlD
Vardenafil—CYP3A4—Doxorubicin—sarcoma	0.0182	0.0509	CbGbCtD
Vardenafil—PDE5A—endothelium—sarcoma	0.00738	0.0763	CbGeAlD
Vardenafil—PDE11A—tendon—sarcoma	0.0063	0.0652	CbGeAlD
Vardenafil—PDE11A—testis—sarcoma	0.00522	0.054	CbGeAlD
Vardenafil—PDE6G—testis—sarcoma	0.00502	0.052	CbGeAlD
Vardenafil—PDE11A—liver—sarcoma	0.00493	0.051	CbGeAlD
Vardenafil—PDE6G—liver—sarcoma	0.00475	0.0491	CbGeAlD
Vardenafil—PDE10A—tendon—sarcoma	0.0041	0.0424	CbGeAlD
Vardenafil—PDE6G—lymph node—sarcoma	0.00364	0.0377	CbGeAlD
Vardenafil—PDE5A—hematopoietic system—sarcoma	0.00362	0.0375	CbGeAlD
Vardenafil—PDE5A—connective tissue—sarcoma	0.00349	0.0361	CbGeAlD
Vardenafil—PDE10A—testis—sarcoma	0.00339	0.0351	CbGeAlD
Vardenafil—PDE1B—testis—sarcoma	0.00336	0.0348	CbGeAlD
Vardenafil—PDE5A—smooth muscle tissue—sarcoma	0.00319	0.033	CbGeAlD
Vardenafil—PDE10A—lymph node—sarcoma	0.00246	0.0254	CbGeAlD
Vardenafil—PDE1B—lymph node—sarcoma	0.00244	0.0252	CbGeAlD
Vardenafil—PDE5A—tendon—sarcoma	0.0024	0.0248	CbGeAlD
Vardenafil—PDE5A—testis—sarcoma	0.00199	0.0205	CbGeAlD
Vardenafil—CYP3A5—hematopoietic system—sarcoma	0.00151	0.0156	CbGeAlD
Vardenafil—PDE5A—lymph node—sarcoma	0.00144	0.0149	CbGeAlD
Vardenafil—CYP3A4—hematopoietic system—sarcoma	0.00113	0.0117	CbGeAlD
Vardenafil—CYP3A5—liver—sarcoma	0.00078	0.00807	CbGeAlD
Vardenafil—Paraesthesia—Vincristine—sarcoma	0.000754	0.002	CcSEcCtD
Vardenafil—Malaise—Etoposide—sarcoma	0.000751	0.00199	CcSEcCtD
Vardenafil—Face oedema—Epirubicin—sarcoma	0.000749	0.00198	CcSEcCtD
Vardenafil—Vertigo—Etoposide—sarcoma	0.000749	0.00198	CcSEcCtD
Vardenafil—Abdominal pain—Thiotepa—sarcoma	0.000748	0.00198	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000745	0.00197	CcSEcCtD
Vardenafil—Abdominal pain—Dactinomycin—sarcoma	0.000743	0.00197	CcSEcCtD
Vardenafil—Paraesthesia—Mitoxantrone—sarcoma	0.000734	0.00194	CcSEcCtD
Vardenafil—Loss of consciousness—Etoposide—sarcoma	0.000732	0.00194	CcSEcCtD
Vardenafil—Dyspnoea—Mitoxantrone—sarcoma	0.000729	0.00193	CcSEcCtD
Vardenafil—Somnolence—Mitoxantrone—sarcoma	0.000727	0.00192	CcSEcCtD
Vardenafil—Blood creatinine increased—Epirubicin—sarcoma	0.000727	0.00192	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Vincristine—sarcoma	0.000725	0.00192	CcSEcCtD
Vardenafil—Convulsion—Etoposide—sarcoma	0.000722	0.00191	CcSEcCtD
Vardenafil—Dyspepsia—Mitoxantrone—sarcoma	0.00072	0.00191	CcSEcCtD
Vardenafil—Pain—Vincristine—sarcoma	0.000718	0.0019	CcSEcCtD
Vardenafil—Liver function test abnormal—Epirubicin—sarcoma	0.000716	0.0019	CcSEcCtD
Vardenafil—Chest pain—Etoposide—sarcoma	0.000709	0.00188	CcSEcCtD
Vardenafil—Orthostatic hypotension—Epirubicin—sarcoma	0.000708	0.00188	CcSEcCtD
Vardenafil—Abdominal pain upper—Epirubicin—sarcoma	0.000708	0.00188	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000705	0.00186	CcSEcCtD
Vardenafil—Discomfort—Etoposide—sarcoma	0.000701	0.00186	CcSEcCtD
Vardenafil—Breast disorder—Epirubicin—sarcoma	0.000701	0.00186	CcSEcCtD
Vardenafil—Pain—Mitoxantrone—sarcoma	0.000699	0.00185	CcSEcCtD
Vardenafil—Aspartate aminotransferase increased—Epirubicin—sarcoma	0.000698	0.00185	CcSEcCtD
Vardenafil—Hypersensitivity—Thiotepa—sarcoma	0.000698	0.00185	CcSEcCtD
Vardenafil—Face oedema—Doxorubicin—sarcoma	0.000693	0.00183	CcSEcCtD
Vardenafil—Hypersensitivity—Dactinomycin—sarcoma	0.000692	0.00183	CcSEcCtD
Vardenafil—Gastrointestinal pain—Vincristine—sarcoma	0.000687	0.00182	CcSEcCtD
Vardenafil—Gastritis—Epirubicin—sarcoma	0.000686	0.00182	CcSEcCtD
Vardenafil—Alanine aminotransferase increased—Epirubicin—sarcoma	0.000684	0.00181	CcSEcCtD
Vardenafil—Anaphylactic shock—Etoposide—sarcoma	0.00068	0.0018	CcSEcCtD
Vardenafil—Asthenia—Thiotepa—sarcoma	0.000679	0.0018	CcSEcCtD
Vardenafil—Infection—Etoposide—sarcoma	0.000676	0.00179	CcSEcCtD
Vardenafil—Asthenia—Dactinomycin—sarcoma	0.000674	0.00178	CcSEcCtD
Vardenafil—Feeling abnormal—Mitoxantrone—sarcoma	0.000674	0.00178	CcSEcCtD
Vardenafil—Blood creatinine increased—Doxorubicin—sarcoma	0.000672	0.00178	CcSEcCtD
Vardenafil—Dysphagia—Epirubicin—sarcoma	0.00067	0.00177	CcSEcCtD
Vardenafil—Influenza—Epirubicin—sarcoma	0.00067	0.00177	CcSEcCtD
Vardenafil—Pruritus—Thiotepa—sarcoma	0.00067	0.00177	CcSEcCtD
Vardenafil—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000669	0.00177	CcSEcCtD
Vardenafil—Tachycardia—Etoposide—sarcoma	0.000664	0.00176	CcSEcCtD
Vardenafil—Abdominal pain—Vincristine—sarcoma	0.000664	0.00176	CcSEcCtD
Vardenafil—Liver function test abnormal—Doxorubicin—sarcoma	0.000663	0.00175	CcSEcCtD
Vardenafil—Skin disorder—Etoposide—sarcoma	0.000661	0.00175	CcSEcCtD
Vardenafil—Hyperhidrosis—Etoposide—sarcoma	0.000657	0.00174	CcSEcCtD
Vardenafil—Orthostatic hypotension—Doxorubicin—sarcoma	0.000656	0.00174	CcSEcCtD
Vardenafil—Abdominal pain upper—Doxorubicin—sarcoma	0.000656	0.00174	CcSEcCtD
Vardenafil—Angina pectoris—Epirubicin—sarcoma	0.000653	0.00173	CcSEcCtD
Vardenafil—Breast disorder—Doxorubicin—sarcoma	0.000649	0.00172	CcSEcCtD
Vardenafil—Diarrhoea—Thiotepa—sarcoma	0.000648	0.00171	CcSEcCtD
Vardenafil—Abdominal pain—Mitoxantrone—sarcoma	0.000646	0.00171	CcSEcCtD
Vardenafil—Aspartate aminotransferase increased—Doxorubicin—sarcoma	0.000646	0.00171	CcSEcCtD
Vardenafil—Diarrhoea—Dactinomycin—sarcoma	0.000643	0.0017	CcSEcCtD
Vardenafil—Hypotension—Etoposide—sarcoma	0.000636	0.00168	CcSEcCtD
Vardenafil—Gastritis—Doxorubicin—sarcoma	0.000635	0.00168	CcSEcCtD
Vardenafil—Alanine aminotransferase increased—Doxorubicin—sarcoma	0.000633	0.00168	CcSEcCtD
Vardenafil—Dizziness—Thiotepa—sarcoma	0.000626	0.00166	CcSEcCtD
Vardenafil—Influenza—Doxorubicin—sarcoma	0.00062	0.00164	CcSEcCtD
Vardenafil—Dysphagia—Doxorubicin—sarcoma	0.00062	0.00164	CcSEcCtD
Vardenafil—Hypersensitivity—Vincristine—sarcoma	0.000619	0.00164	CcSEcCtD
Vardenafil—Photosensitivity reaction—Epirubicin—sarcoma	0.000612	0.00162	CcSEcCtD
Vardenafil—Paraesthesia—Etoposide—sarcoma	0.000611	0.00162	CcSEcCtD
Vardenafil—Dyspnoea—Etoposide—sarcoma	0.000606	0.0016	CcSEcCtD
Vardenafil—Somnolence—Etoposide—sarcoma	0.000605	0.0016	CcSEcCtD
Vardenafil—Angina pectoris—Doxorubicin—sarcoma	0.000604	0.0016	CcSEcCtD
Vardenafil—Hypersensitivity—Mitoxantrone—sarcoma	0.000602	0.00159	CcSEcCtD
Vardenafil—Asthenia—Vincristine—sarcoma	0.000602	0.00159	CcSEcCtD
Vardenafil—Vomiting—Thiotepa—sarcoma	0.000602	0.00159	CcSEcCtD
Vardenafil—Infestation NOS—Epirubicin—sarcoma	0.000598	0.00158	CcSEcCtD
Vardenafil—Infestation—Epirubicin—sarcoma	0.000598	0.00158	CcSEcCtD
Vardenafil—Vomiting—Dactinomycin—sarcoma	0.000597	0.00158	CcSEcCtD
Vardenafil—Rash—Thiotepa—sarcoma	0.000597	0.00158	CcSEcCtD
Vardenafil—Dermatitis—Thiotepa—sarcoma	0.000596	0.00158	CcSEcCtD
Vardenafil—Headache—Thiotepa—sarcoma	0.000593	0.00157	CcSEcCtD
Vardenafil—Rash—Dactinomycin—sarcoma	0.000592	0.00157	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Etoposide—sarcoma	0.000587	0.00155	CcSEcCtD
Vardenafil—Asthenia—Mitoxantrone—sarcoma	0.000587	0.00155	CcSEcCtD
Vardenafil—CYP3A4—liver—sarcoma	0.000585	0.00605	CbGeAlD
Vardenafil—Pain—Etoposide—sarcoma	0.000582	0.00154	CcSEcCtD
Vardenafil—Conjunctivitis—Epirubicin—sarcoma	0.000581	0.00154	CcSEcCtD
Vardenafil—Diarrhoea—Vincristine—sarcoma	0.000574	0.00152	CcSEcCtD
Vardenafil—Sweating—Epirubicin—sarcoma	0.000573	0.00152	CcSEcCtD
Vardenafil—Haematuria—Epirubicin—sarcoma	0.00057	0.00151	CcSEcCtD
Vardenafil—Photosensitivity reaction—Doxorubicin—sarcoma	0.000566	0.0015	CcSEcCtD
Vardenafil—Hepatobiliary disease—Epirubicin—sarcoma	0.000565	0.0015	CcSEcCtD
Vardenafil—Epistaxis—Epirubicin—sarcoma	0.000564	0.00149	CcSEcCtD
Vardenafil—Nausea—Thiotepa—sarcoma	0.000562	0.00149	CcSEcCtD
Vardenafil—Sinusitis—Epirubicin—sarcoma	0.000561	0.00148	CcSEcCtD
Vardenafil—Feeling abnormal—Etoposide—sarcoma	0.00056	0.00148	CcSEcCtD
Vardenafil—Diarrhoea—Mitoxantrone—sarcoma	0.000559	0.00148	CcSEcCtD
Vardenafil—Nausea—Dactinomycin—sarcoma	0.000558	0.00148	CcSEcCtD
Vardenafil—Gastrointestinal pain—Etoposide—sarcoma	0.000556	0.00147	CcSEcCtD
Vardenafil—Dizziness—Vincristine—sarcoma	0.000555	0.00147	CcSEcCtD
Vardenafil—Infestation NOS—Doxorubicin—sarcoma	0.000553	0.00146	CcSEcCtD
Vardenafil—Infestation—Doxorubicin—sarcoma	0.000553	0.00146	CcSEcCtD
Vardenafil—Haemoglobin—Epirubicin—sarcoma	0.000539	0.00143	CcSEcCtD
Vardenafil—Rhinitis—Epirubicin—sarcoma	0.000538	0.00142	CcSEcCtD
Vardenafil—Abdominal pain—Etoposide—sarcoma	0.000538	0.00142	CcSEcCtD
Vardenafil—Conjunctivitis—Doxorubicin—sarcoma	0.000538	0.00142	CcSEcCtD
Vardenafil—Haemorrhage—Epirubicin—sarcoma	0.000537	0.00142	CcSEcCtD
Vardenafil—Hypoaesthesia—Epirubicin—sarcoma	0.000534	0.00141	CcSEcCtD
Vardenafil—Vomiting—Vincristine—sarcoma	0.000534	0.00141	CcSEcCtD
Vardenafil—Pharyngitis—Epirubicin—sarcoma	0.000533	0.00141	CcSEcCtD
Vardenafil—Sweating—Doxorubicin—sarcoma	0.00053	0.0014	CcSEcCtD
Vardenafil—Urinary tract disorder—Epirubicin—sarcoma	0.00053	0.0014	CcSEcCtD
Vardenafil—Rash—Vincristine—sarcoma	0.000529	0.0014	CcSEcCtD
Vardenafil—Dermatitis—Vincristine—sarcoma	0.000529	0.0014	CcSEcCtD
Vardenafil—Haematuria—Doxorubicin—sarcoma	0.000527	0.0014	CcSEcCtD
Vardenafil—Connective tissue disorder—Epirubicin—sarcoma	0.000527	0.0014	CcSEcCtD
Vardenafil—Urethral disorder—Epirubicin—sarcoma	0.000526	0.00139	CcSEcCtD
Vardenafil—Headache—Vincristine—sarcoma	0.000526	0.00139	CcSEcCtD
Vardenafil—Hepatobiliary disease—Doxorubicin—sarcoma	0.000523	0.00138	CcSEcCtD
Vardenafil—Epistaxis—Doxorubicin—sarcoma	0.000522	0.00138	CcSEcCtD
Vardenafil—Vomiting—Mitoxantrone—sarcoma	0.00052	0.00138	CcSEcCtD
Vardenafil—Sinusitis—Doxorubicin—sarcoma	0.000519	0.00137	CcSEcCtD
Vardenafil—Visual impairment—Epirubicin—sarcoma	0.000517	0.00137	CcSEcCtD
Vardenafil—Rash—Mitoxantrone—sarcoma	0.000516	0.00136	CcSEcCtD
Vardenafil—Dermatitis—Mitoxantrone—sarcoma	0.000515	0.00136	CcSEcCtD
Vardenafil—Headache—Mitoxantrone—sarcoma	0.000512	0.00136	CcSEcCtD
Vardenafil—Eye disorder—Epirubicin—sarcoma	0.000501	0.00133	CcSEcCtD
Vardenafil—Hypersensitivity—Etoposide—sarcoma	0.000501	0.00133	CcSEcCtD
Vardenafil—Tinnitus—Epirubicin—sarcoma	0.0005	0.00132	CcSEcCtD
Vardenafil—Haemoglobin—Doxorubicin—sarcoma	0.000499	0.00132	CcSEcCtD
Vardenafil—Nausea—Vincristine—sarcoma	0.000499	0.00132	CcSEcCtD
Vardenafil—Cardiac disorder—Epirubicin—sarcoma	0.000498	0.00132	CcSEcCtD
Vardenafil—Flushing—Epirubicin—sarcoma	0.000498	0.00132	CcSEcCtD
Vardenafil—Rhinitis—Doxorubicin—sarcoma	0.000498	0.00132	CcSEcCtD
Vardenafil—Haemorrhage—Doxorubicin—sarcoma	0.000497	0.00131	CcSEcCtD
Vardenafil—Hypoaesthesia—Doxorubicin—sarcoma	0.000494	0.00131	CcSEcCtD
Vardenafil—Pharyngitis—Doxorubicin—sarcoma	0.000493	0.0013	CcSEcCtD
Vardenafil—Urinary tract disorder—Doxorubicin—sarcoma	0.00049	0.0013	CcSEcCtD
Vardenafil—Asthenia—Etoposide—sarcoma	0.000488	0.00129	CcSEcCtD
Vardenafil—Connective tissue disorder—Doxorubicin—sarcoma	0.000488	0.00129	CcSEcCtD
Vardenafil—Angiopathy—Epirubicin—sarcoma	0.000487	0.00129	CcSEcCtD
Vardenafil—Urethral disorder—Doxorubicin—sarcoma	0.000487	0.00129	CcSEcCtD
Vardenafil—Nausea—Mitoxantrone—sarcoma	0.000486	0.00129	CcSEcCtD
Vardenafil—Immune system disorder—Epirubicin—sarcoma	0.000485	0.00128	CcSEcCtD
Vardenafil—Mediastinal disorder—Epirubicin—sarcoma	0.000484	0.00128	CcSEcCtD
Vardenafil—Pruritus—Etoposide—sarcoma	0.000481	0.00127	CcSEcCtD
Vardenafil—Visual impairment—Doxorubicin—sarcoma	0.000478	0.00127	CcSEcCtD
Vardenafil—Mental disorder—Epirubicin—sarcoma	0.00047	0.00124	CcSEcCtD
Vardenafil—Erythema—Epirubicin—sarcoma	0.000467	0.00124	CcSEcCtD
Vardenafil—Diarrhoea—Etoposide—sarcoma	0.000465	0.00123	CcSEcCtD
Vardenafil—Eye disorder—Doxorubicin—sarcoma	0.000464	0.00123	CcSEcCtD
Vardenafil—Tinnitus—Doxorubicin—sarcoma	0.000463	0.00123	CcSEcCtD
Vardenafil—Flushing—Doxorubicin—sarcoma	0.000461	0.00122	CcSEcCtD
Vardenafil—Cardiac disorder—Doxorubicin—sarcoma	0.000461	0.00122	CcSEcCtD
Vardenafil—Back pain—Epirubicin—sarcoma	0.000452	0.0012	CcSEcCtD
Vardenafil—Angiopathy—Doxorubicin—sarcoma	0.00045	0.00119	CcSEcCtD
Vardenafil—Dizziness—Etoposide—sarcoma	0.00045	0.00119	CcSEcCtD
Vardenafil—Muscle spasms—Epirubicin—sarcoma	0.000449	0.00119	CcSEcCtD
Vardenafil—Immune system disorder—Doxorubicin—sarcoma	0.000448	0.00119	CcSEcCtD
Vardenafil—Mediastinal disorder—Doxorubicin—sarcoma	0.000447	0.00118	CcSEcCtD
Vardenafil—Vision blurred—Epirubicin—sarcoma	0.00044	0.00117	CcSEcCtD
Vardenafil—Mental disorder—Doxorubicin—sarcoma	0.000435	0.00115	CcSEcCtD
Vardenafil—Ill-defined disorder—Epirubicin—sarcoma	0.000433	0.00115	CcSEcCtD
Vardenafil—Vomiting—Etoposide—sarcoma	0.000432	0.00114	CcSEcCtD
Vardenafil—Erythema—Doxorubicin—sarcoma	0.000432	0.00114	CcSEcCtD
Vardenafil—Rash—Etoposide—sarcoma	0.000429	0.00114	CcSEcCtD
Vardenafil—Dermatitis—Etoposide—sarcoma	0.000428	0.00113	CcSEcCtD
Vardenafil—Headache—Etoposide—sarcoma	0.000426	0.00113	CcSEcCtD
Vardenafil—Malaise—Epirubicin—sarcoma	0.000421	0.00112	CcSEcCtD
Vardenafil—Vertigo—Epirubicin—sarcoma	0.00042	0.00111	CcSEcCtD
Vardenafil—Syncope—Epirubicin—sarcoma	0.000419	0.00111	CcSEcCtD
Vardenafil—Back pain—Doxorubicin—sarcoma	0.000418	0.00111	CcSEcCtD
Vardenafil—Muscle spasms—Doxorubicin—sarcoma	0.000416	0.0011	CcSEcCtD
Vardenafil—Palpitations—Epirubicin—sarcoma	0.000413	0.00109	CcSEcCtD
Vardenafil—Loss of consciousness—Epirubicin—sarcoma	0.000411	0.00109	CcSEcCtD
Vardenafil—Vision blurred—Doxorubicin—sarcoma	0.000407	0.00108	CcSEcCtD
Vardenafil—Convulsion—Epirubicin—sarcoma	0.000405	0.00107	CcSEcCtD
Vardenafil—Nausea—Etoposide—sarcoma	0.000404	0.00107	CcSEcCtD
Vardenafil—Ill-defined disorder—Doxorubicin—sarcoma	0.000401	0.00106	CcSEcCtD
Vardenafil—Myalgia—Epirubicin—sarcoma	0.000398	0.00105	CcSEcCtD
Vardenafil—Arthralgia—Epirubicin—sarcoma	0.000398	0.00105	CcSEcCtD
Vardenafil—Chest pain—Epirubicin—sarcoma	0.000398	0.00105	CcSEcCtD
Vardenafil—Anxiety—Epirubicin—sarcoma	0.000396	0.00105	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000395	0.00105	CcSEcCtD
Vardenafil—Discomfort—Epirubicin—sarcoma	0.000393	0.00104	CcSEcCtD
Vardenafil—Malaise—Doxorubicin—sarcoma	0.00039	0.00103	CcSEcCtD
Vardenafil—Dry mouth—Epirubicin—sarcoma	0.000389	0.00103	CcSEcCtD
Vardenafil—Vertigo—Doxorubicin—sarcoma	0.000388	0.00103	CcSEcCtD
Vardenafil—Syncope—Doxorubicin—sarcoma	0.000388	0.00103	CcSEcCtD
Vardenafil—Palpitations—Doxorubicin—sarcoma	0.000382	0.00101	CcSEcCtD
Vardenafil—Anaphylactic shock—Epirubicin—sarcoma	0.000381	0.00101	CcSEcCtD
Vardenafil—Loss of consciousness—Doxorubicin—sarcoma	0.00038	0.00101	CcSEcCtD
Vardenafil—Infection—Epirubicin—sarcoma	0.000379	0.001	CcSEcCtD
Vardenafil—Shock—Epirubicin—sarcoma	0.000375	0.000993	CcSEcCtD
Vardenafil—Convulsion—Doxorubicin—sarcoma	0.000374	0.000991	CcSEcCtD
Vardenafil—Nervous system disorder—Epirubicin—sarcoma	0.000374	0.00099	CcSEcCtD
Vardenafil—Tachycardia—Epirubicin—sarcoma	0.000372	0.000985	CcSEcCtD
Vardenafil—Skin disorder—Epirubicin—sarcoma	0.00037	0.00098	CcSEcCtD
Vardenafil—Hyperhidrosis—Epirubicin—sarcoma	0.000369	0.000976	CcSEcCtD
Vardenafil—Arthralgia—Doxorubicin—sarcoma	0.000368	0.000974	CcSEcCtD
Vardenafil—Chest pain—Doxorubicin—sarcoma	0.000368	0.000974	CcSEcCtD
Vardenafil—Myalgia—Doxorubicin—sarcoma	0.000368	0.000974	CcSEcCtD
Vardenafil—Anxiety—Doxorubicin—sarcoma	0.000367	0.000971	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000365	0.000967	CcSEcCtD
Vardenafil—Discomfort—Doxorubicin—sarcoma	0.000364	0.000962	CcSEcCtD
Vardenafil—Dry mouth—Doxorubicin—sarcoma	0.00036	0.000953	CcSEcCtD
Vardenafil—Hypotension—Epirubicin—sarcoma	0.000356	0.000943	CcSEcCtD
Vardenafil—Anaphylactic shock—Doxorubicin—sarcoma	0.000353	0.000934	CcSEcCtD
Vardenafil—Infection—Doxorubicin—sarcoma	0.00035	0.000928	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000347	0.000919	CcSEcCtD
Vardenafil—Shock—Doxorubicin—sarcoma	0.000347	0.000919	CcSEcCtD
Vardenafil—Nervous system disorder—Doxorubicin—sarcoma	0.000346	0.000916	CcSEcCtD
Vardenafil—Insomnia—Epirubicin—sarcoma	0.000345	0.000913	CcSEcCtD
Vardenafil—Tachycardia—Doxorubicin—sarcoma	0.000344	0.000911	CcSEcCtD
Vardenafil—Skin disorder—Doxorubicin—sarcoma	0.000343	0.000907	CcSEcCtD
Vardenafil—Paraesthesia—Epirubicin—sarcoma	0.000342	0.000906	CcSEcCtD
Vardenafil—Hyperhidrosis—Doxorubicin—sarcoma	0.000341	0.000903	CcSEcCtD
Vardenafil—Dyspnoea—Epirubicin—sarcoma	0.00034	0.0009	CcSEcCtD
Vardenafil—Somnolence—Epirubicin—sarcoma	0.000339	0.000897	CcSEcCtD
Vardenafil—Dyspepsia—Epirubicin—sarcoma	0.000336	0.000888	CcSEcCtD
Vardenafil—Hypotension—Doxorubicin—sarcoma	0.00033	0.000872	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Epirubicin—sarcoma	0.000329	0.000871	CcSEcCtD
Vardenafil—Pain—Epirubicin—sarcoma	0.000326	0.000863	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000321	0.000851	CcSEcCtD
Vardenafil—Insomnia—Doxorubicin—sarcoma	0.000319	0.000844	CcSEcCtD
Vardenafil—Paraesthesia—Doxorubicin—sarcoma	0.000317	0.000838	CcSEcCtD
Vardenafil—Dyspnoea—Doxorubicin—sarcoma	0.000314	0.000832	CcSEcCtD
Vardenafil—Feeling abnormal—Epirubicin—sarcoma	0.000314	0.000832	CcSEcCtD
Vardenafil—Somnolence—Doxorubicin—sarcoma	0.000314	0.00083	CcSEcCtD
Vardenafil—Gastrointestinal pain—Epirubicin—sarcoma	0.000312	0.000825	CcSEcCtD
Vardenafil—Dyspepsia—Doxorubicin—sarcoma	0.000311	0.000822	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000305	0.000806	CcSEcCtD
Vardenafil—Pain—Doxorubicin—sarcoma	0.000302	0.000798	CcSEcCtD
Vardenafil—Abdominal pain—Epirubicin—sarcoma	0.000301	0.000798	CcSEcCtD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—NRAS—sarcoma	0.000296	0.00177	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—EGFR—sarcoma	0.000294	0.00177	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—NRAS—sarcoma	0.000294	0.00177	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CXCR4—sarcoma	0.000293	0.00176	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—EGFR—sarcoma	0.000293	0.00176	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—EGFR—sarcoma	0.000291	0.00175	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—VEGFA—sarcoma	0.000291	0.00175	CbGpPWpGaD
Vardenafil—Feeling abnormal—Doxorubicin—sarcoma	0.000291	0.000769	CcSEcCtD
Vardenafil—PDE11A—Signaling Pathways—ATF1—sarcoma	0.00029	0.00174	CbGpPWpGaD
Vardenafil—Gastrointestinal pain—Doxorubicin—sarcoma	0.000288	0.000764	CcSEcCtD
Vardenafil—PDE11A—Hemostasis—NRAS—sarcoma	0.000287	0.00172	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—FLT1—sarcoma	0.000284	0.0017	CbGpPWpGaD
Vardenafil—PDE6G—Disease—FOXO1—sarcoma	0.000283	0.0017	CbGpPWpGaD
Vardenafil—PDE6G—Disease—PDGFRB—sarcoma	0.000282	0.00169	CbGpPWpGaD
Vardenafil—Hypersensitivity—Epirubicin—sarcoma	0.000281	0.000743	CcSEcCtD
Vardenafil—PDE1B—Downstream signal transduction—KRAS—sarcoma	0.000279	0.00168	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PLCG1—sarcoma	0.000279	0.00167	CbGpPWpGaD
Vardenafil—Abdominal pain—Doxorubicin—sarcoma	0.000279	0.000738	CcSEcCtD
Vardenafil—PDE1B—Signaling by FGFR—KRAS—sarcoma	0.000278	0.00167	CbGpPWpGaD
Vardenafil—PDE6G—Disease—PDGFRA—sarcoma	0.000278	0.00167	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—SRC—sarcoma	0.000277	0.00166	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—FLT1—sarcoma	0.000277	0.00166	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—KRAS—sarcoma	0.000277	0.00166	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—KRAS—sarcoma	0.000275	0.00165	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—EGFR—sarcoma	0.000274	0.00164	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—EGFR—sarcoma	0.000274	0.00164	CbGpPWpGaD
Vardenafil—Asthenia—Epirubicin—sarcoma	0.000274	0.000724	CcSEcCtD
Vardenafil—PDE1B—Signaling by NGF—MDM2—sarcoma	0.000273	0.00164	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PLCG1—sarcoma	0.000272	0.00163	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—EGFR—sarcoma	0.000272	0.00163	CbGpPWpGaD
Vardenafil—Pruritus—Epirubicin—sarcoma	0.00027	0.000714	CcSEcCtD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—EGFR—sarcoma	0.000269	0.00162	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CXCR4—sarcoma	0.000268	0.00161	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—EGFR—sarcoma	0.000268	0.00161	CbGpPWpGaD
Vardenafil—PDE1B—Disease—NPM1—sarcoma	0.000268	0.00161	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—NRAS—sarcoma	0.000267	0.0016	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—SRC—sarcoma	0.000266	0.0016	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—SRC—sarcoma	0.000266	0.0016	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—CREB1—sarcoma	0.000266	0.0016	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—ATF1—sarcoma	0.000265	0.00159	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CXCR4—sarcoma	0.000261	0.00157	CbGpPWpGaD
Vardenafil—Diarrhoea—Epirubicin—sarcoma	0.000261	0.00069	CcSEcCtD
Vardenafil—Hypersensitivity—Doxorubicin—sarcoma	0.00026	0.000688	CcSEcCtD
Vardenafil—PDE1B—Innate Immune System—FOXO1—sarcoma	0.00026	0.00156	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—VEGFA—sarcoma	0.000259	0.00156	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—VEGFA—sarcoma	0.000259	0.00156	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—PDGFRB—sarcoma	0.000259	0.00156	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—KRAS—sarcoma	0.000259	0.00155	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—KRAS—sarcoma	0.000259	0.00155	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—ATF1—sarcoma	0.000258	0.00155	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—KRAS—sarcoma	0.000257	0.00154	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—NRAS—sarcoma	0.000256	0.00154	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—NRAS—sarcoma	0.000256	0.00154	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—PDGFRA—sarcoma	0.000255	0.00153	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—KRAS—sarcoma	0.000254	0.00153	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—KRAS—sarcoma	0.000253	0.00152	CbGpPWpGaD
Vardenafil—Asthenia—Doxorubicin—sarcoma	0.000253	0.00067	CcSEcCtD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—HRAS—sarcoma	0.000253	0.00152	CbGpPWpGaD
Vardenafil—Dizziness—Epirubicin—sarcoma	0.000252	0.000667	CcSEcCtD
Vardenafil—Pruritus—Doxorubicin—sarcoma	0.00025	0.000661	CcSEcCtD
Vardenafil—PDE11A—Hemostasis—KRAS—sarcoma	0.000247	0.00148	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—CXCR4—sarcoma	0.000247	0.00148	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—EGFR—sarcoma	0.000243	0.00146	CbGpPWpGaD
Vardenafil—Vomiting—Epirubicin—sarcoma	0.000242	0.000642	CcSEcCtD
Vardenafil—Diarrhoea—Doxorubicin—sarcoma	0.000241	0.000639	CcSEcCtD
Vardenafil—Rash—Epirubicin—sarcoma	0.00024	0.000636	CcSEcCtD
Vardenafil—Dermatitis—Epirubicin—sarcoma	0.00024	0.000636	CcSEcCtD
Vardenafil—Headache—Epirubicin—sarcoma	0.000239	0.000632	CcSEcCtD
Vardenafil—PDE1B—Downstream signal transduction—HRAS—sarcoma	0.000237	0.00142	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—CREB1—sarcoma	0.000237	0.00142	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—HRAS—sarcoma	0.000236	0.00142	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—HRAS—sarcoma	0.000235	0.00141	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—HRAS—sarcoma	0.000234	0.0014	CbGpPWpGaD
Vardenafil—Dizziness—Doxorubicin—sarcoma	0.000233	0.000617	CcSEcCtD
Vardenafil—PDE1B—Disease—ENO2—sarcoma	0.000232	0.00139	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—KRAS—sarcoma	0.000229	0.00138	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—IGF1R—sarcoma	0.000227	0.00136	CbGpPWpGaD
Vardenafil—Nausea—Epirubicin—sarcoma	0.000226	0.000599	CcSEcCtD
Vardenafil—Vomiting—Doxorubicin—sarcoma	0.000224	0.000594	CcSEcCtD
Vardenafil—PDE1B—Signaling by GPCR—CXCR4—sarcoma	0.000224	0.00135	CbGpPWpGaD
Vardenafil—Rash—Doxorubicin—sarcoma	0.000222	0.000589	CcSEcCtD
Vardenafil—Dermatitis—Doxorubicin—sarcoma	0.000222	0.000588	CcSEcCtD
Vardenafil—Headache—Doxorubicin—sarcoma	0.000221	0.000585	CcSEcCtD
Vardenafil—PDE10A—Hemostasis—KRAS—sarcoma	0.000221	0.00132	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—KRAS—sarcoma	0.000221	0.00132	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—HRAS—sarcoma	0.00022	0.00132	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—HRAS—sarcoma	0.00022	0.00132	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—TP53—sarcoma	0.00022	0.00132	CbGpPWpGaD
Vardenafil—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	0.000218	0.00131	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—HRAS—sarcoma	0.000218	0.00131	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PTPRC—sarcoma	0.000218	0.00131	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—FOXO1—sarcoma	0.000217	0.0013	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—IL2—sarcoma	0.000216	0.0013	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—HRAS—sarcoma	0.000216	0.0013	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—PDGFRB—sarcoma	0.000216	0.0013	CbGpPWpGaD
Vardenafil—PDE6G—Disease—KIT—sarcoma	0.000215	0.00129	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—HRAS—sarcoma	0.000215	0.00129	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PLCG1—sarcoma	0.000213	0.00128	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—SRC—sarcoma	0.000213	0.00128	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—PDGFRA—sarcoma	0.000213	0.00128	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—HRAS—sarcoma	0.00021	0.00126	CbGpPWpGaD
Vardenafil—Nausea—Doxorubicin—sarcoma	0.00021	0.000555	CcSEcCtD
Vardenafil—PDE6G—Signaling Pathways—IGF1R—sarcoma	0.000208	0.00125	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TLE1—sarcoma	0.000208	0.00125	CbGpPWpGaD
Vardenafil—PDE6G—Disease—CREB1—sarcoma	0.000205	0.00123	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—NRAS—sarcoma	0.000205	0.00123	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—IGF1R—sarcoma	0.000203	0.00122	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—ATF1—sarcoma	0.000203	0.00122	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—FOXO1—sarcoma	0.000198	0.00119	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—KIT—sarcoma	0.000198	0.00119	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PDGFRB—sarcoma	0.000198	0.00119	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PLCG1—sarcoma	0.000197	0.00118	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—IL2—sarcoma	0.000197	0.00118	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—TP53—sarcoma	0.000196	0.00118	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—TP53—sarcoma	0.000196	0.00118	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—HRAS—sarcoma	0.000195	0.00117	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PDGFRA—sarcoma	0.000195	0.00117	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—FOXO1—sarcoma	0.000193	0.00116	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—IL2—sarcoma	0.000193	0.00116	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PDGFRB—sarcoma	0.000193	0.00116	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PDGFRA—sarcoma	0.00019	0.00114	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CXCR4—sarcoma	0.000189	0.00113	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—CREB1—sarcoma	0.000188	0.00113	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—HRAS—sarcoma	0.000187	0.00112	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—HRAS—sarcoma	0.000187	0.00112	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—EGFR—sarcoma	0.000187	0.00112	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—KDR—sarcoma	0.000179	0.00107	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—KRAS—sarcoma	0.000176	0.00106	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—VEGFC—sarcoma	0.000175	0.00105	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—IL2—sarcoma	0.000175	0.00105	CbGpPWpGaD
Vardenafil—PDE6G—Disease—MDM2—sarcoma	0.00017	0.00102	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—KIT—sarcoma	0.000165	0.00099	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—NRAS—sarcoma	0.000165	0.00099	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—KDR—sarcoma	0.000164	0.000983	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—KDR—sarcoma	0.00016	0.000958	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CREB1—sarcoma	0.000157	0.000942	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—MDM2—sarcoma	0.000156	0.000935	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—IL2—sarcoma	0.000155	0.000928	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—FOXO1—sarcoma	0.000151	0.000908	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PDGFRB—sarcoma	0.000151	0.000906	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—KIT—sarcoma	0.000151	0.000905	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—EGFR—sarcoma	0.00015	0.000902	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—HRAS—sarcoma	0.00015	0.0009	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PDGFRA—sarcoma	0.000149	0.000892	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—KIT—sarcoma	0.000147	0.000882	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—NRAS—sarcoma	0.000147	0.000882	CbGpPWpGaD
Vardenafil—PDE6G—Disease—CTNNB1—sarcoma	0.000146	0.000878	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CREB1—sarcoma	0.000144	0.000862	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—KRAS—sarcoma	0.000142	0.000852	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—FLT1—sarcoma	0.00014	0.000841	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CREB1—sarcoma	0.00014	0.00084	CbGpPWpGaD
Vardenafil—PDE1B—Disease—FOXO1—sarcoma	0.00014	0.000838	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PDGFRB—sarcoma	0.000139	0.000837	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PLCG1—sarcoma	0.000138	0.000827	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PDGFRA—sarcoma	0.000137	0.000824	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—JUN—sarcoma	0.000135	0.000813	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—SRC—sarcoma	0.000135	0.00081	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—CTNNB1—sarcoma	0.000134	0.000807	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—EGFR—sarcoma	0.000134	0.000804	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CXCR4—sarcoma	0.000132	0.000795	CbGpPWpGaD
Vardenafil—PDE6G—Disease—SRC—sarcoma	0.000132	0.000794	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—VEGFA—sarcoma	0.000131	0.000789	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—ATF1—sarcoma	0.000131	0.000786	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—MDM2—sarcoma	0.00013	0.00078	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—NRAS—sarcoma	0.00013	0.000779	CbGpPWpGaD
Vardenafil—PDE6G—Disease—NRAS—sarcoma	0.000127	0.000764	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—KRAS—sarcoma	0.000127	0.000759	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—SRC—sarcoma	0.000122	0.000729	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—HRAS—sarcoma	0.000121	0.000724	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—CREB1—sarcoma	0.00012	0.000721	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—MDM2—sarcoma	0.000119	0.000713	CbGpPWpGaD
Vardenafil—PDE6G—Disease—MYC—sarcoma	0.000119	0.000711	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—NRAS—sarcoma	0.000117	0.000701	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—IL2—sarcoma	0.000116	0.000697	CbGpPWpGaD
Vardenafil—PDE6G—Disease—EGFR—sarcoma	0.000116	0.000696	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—MDM2—sarcoma	0.000116	0.000695	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—KIT—sarcoma	0.000115	0.000692	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CCND1—sarcoma	0.000113	0.000679	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—JUN—sarcoma	0.000113	0.000678	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CTNNB1—sarcoma	0.000112	0.000673	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—KRAS—sarcoma	0.000112	0.000671	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CREB1—sarcoma	0.00011	0.000658	CbGpPWpGaD
Vardenafil—PDE6G—Disease—KRAS—sarcoma	0.00011	0.000657	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—HRAS—sarcoma	0.000108	0.000645	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—EGFR—sarcoma	0.000107	0.000639	CbGpPWpGaD
Vardenafil—PDE1B—Disease—KIT—sarcoma	0.000106	0.000639	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—IL2—sarcoma	0.000106	0.000637	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CCND1—sarcoma	0.000104	0.000621	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—IL2—sarcoma	0.000103	0.000621	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—JUN—sarcoma	0.000103	0.00062	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—IGF1R—sarcoma	0.000103	0.000617	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CTNNB1—sarcoma	0.000103	0.000615	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—SRC—sarcoma	0.000101	0.000608	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CREB1—sarcoma	0.000101	0.000608	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CCND1—sarcoma	0.000101	0.000605	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—JUN—sarcoma	0.000101	0.000604	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—KRAS—sarcoma	0.000101	0.000604	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CTNNB1—sarcoma	9.99e-05	0.000599	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—TP53—sarcoma	9.93e-05	0.000596	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—VEGFA—sarcoma	9.87e-05	0.000592	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—FOXO1—sarcoma	9.78e-05	0.000587	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—IL2—sarcoma	9.78e-05	0.000587	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PDGFRB—sarcoma	9.76e-05	0.000586	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—NRAS—sarcoma	9.75e-05	0.000585	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PDGFRA—sarcoma	9.61e-05	0.000577	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—HRAS—sarcoma	9.5e-05	0.00057	CbGpPWpGaD
Vardenafil—PDE6G—Disease—HRAS—sarcoma	9.31e-05	0.000559	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—SRC—sarcoma	9.27e-05	0.000556	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—MYC—sarcoma	9.08e-05	0.000545	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—MDM2—sarcoma	9.08e-05	0.000545	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—SRC—sarcoma	9.03e-05	0.000542	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—VEGFA—sarcoma	9.03e-05	0.000541	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—NRAS—sarcoma	8.91e-05	0.000535	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—EGFR—sarcoma	8.88e-05	0.000533	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—IL2—sarcoma	8.88e-05	0.000533	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—VEGFA—sarcoma	8.8e-05	0.000528	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—NRAS—sarcoma	8.69e-05	0.000521	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—HRAS—sarcoma	8.55e-05	0.000513	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—KRAS—sarcoma	8.39e-05	0.000503	CbGpPWpGaD
Vardenafil—PDE1B—Disease—MDM2—sarcoma	8.38e-05	0.000503	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—MYC—sarcoma	8.3e-05	0.000498	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—EGFR—sarcoma	8.12e-05	0.000487	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—IL2—sarcoma	8.11e-05	0.000487	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—MYC—sarcoma	8.09e-05	0.000486	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—KDR—sarcoma	8.09e-05	0.000485	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—EGFR—sarcoma	7.91e-05	0.000475	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—JUN—sarcoma	7.89e-05	0.000473	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CTNNB1—sarcoma	7.83e-05	0.00047	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—ENO2—sarcoma	7.74e-05	0.000464	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—HBA1—sarcoma	7.69e-05	0.000461	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—KRAS—sarcoma	7.67e-05	0.00046	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—KRAS—sarcoma	7.48e-05	0.000449	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—TP53—sarcoma	7.46e-05	0.000447	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—KIT—sarcoma	7.45e-05	0.000447	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—NRAS—sarcoma	7.45e-05	0.000447	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CTNNB1—sarcoma	7.23e-05	0.000434	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—HRAS—sarcoma	7.13e-05	0.000428	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CREB1—sarcoma	7.09e-05	0.000426	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—SRC—sarcoma	7.08e-05	0.000425	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—TP53—sarcoma	6.82e-05	0.000409	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—NRAS—sarcoma	6.81e-05	0.000409	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—EGFR—sarcoma	6.79e-05	0.000407	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—TP53—sarcoma	6.65e-05	0.000399	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PLCG1—sarcoma	6.56e-05	0.000394	CbGpPWpGaD
Vardenafil—PDE1B—Disease—SRC—sarcoma	6.54e-05	0.000392	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—HRAS—sarcoma	6.52e-05	0.000391	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—KRAS—sarcoma	6.41e-05	0.000385	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—HRAS—sarcoma	6.36e-05	0.000381	CbGpPWpGaD
Vardenafil—PDE1B—Disease—NRAS—sarcoma	6.29e-05	0.000377	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—EGFR—sarcoma	6.2e-05	0.000372	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MDM2—sarcoma	5.87e-05	0.000352	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—KRAS—sarcoma	5.86e-05	0.000352	CbGpPWpGaD
Vardenafil—PDE1B—Disease—MYC—sarcoma	5.86e-05	0.000351	CbGpPWpGaD
Vardenafil—PDE1B—Disease—EGFR—sarcoma	5.73e-05	0.000344	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—HRAS—sarcoma	5.45e-05	0.000327	CbGpPWpGaD
Vardenafil—PDE1B—Disease—KRAS—sarcoma	5.41e-05	0.000325	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—IL2—sarcoma	5.24e-05	0.000315	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CCND1—sarcoma	5.11e-05	0.000307	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—JUN—sarcoma	5.1e-05	0.000306	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CTNNB1—sarcoma	5.06e-05	0.000304	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—HRAS—sarcoma	4.98e-05	0.000299	CbGpPWpGaD
Vardenafil—PDE1B—Disease—HRAS—sarcoma	4.6e-05	0.000276	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—SRC—sarcoma	4.58e-05	0.000275	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—VEGFA—sarcoma	4.46e-05	0.000267	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—NRAS—sarcoma	4.4e-05	0.000264	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MYC—sarcoma	4.1e-05	0.000246	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—EGFR—sarcoma	4.01e-05	0.000241	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—KRAS—sarcoma	3.79e-05	0.000227	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—ENO2—sarcoma	3.6e-05	0.000216	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—HBA1—sarcoma	3.57e-05	0.000214	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TP53—sarcoma	3.37e-05	0.000202	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—HRAS—sarcoma	3.22e-05	0.000193	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PLCG1—sarcoma	3.05e-05	0.000183	CbGpPWpGaD
